Tuesday, September 20, 2022

ImmunoScape Finds $24M From Amgen, Others

San Diego-based ImmunoScape, a biotech company which says it is focused on discovery and development of next-generation TCR-T-cell therapeutics, has raised $14M in a funding round. The funding was led by Anzu Partners, and also included Amgen Ventures and Singapore's EDBI. The company said it is focused on discovery and in-depth characterization of rare

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.